X4 Pharmaceuticals

XFOR · NASDAQ

$3.02+$0.27 (+9.82%)TodayMarket closed · Oct 20, 7:30 PM ET

Prev close $2.75

XFOR analyst rating

BuyConsensus of 5 analysts over the last 12 months. 100% rate it a buy.

Strong buy0
Buy5
Hold0
Underperform0
Sell0

12-month price target · 7 analysts

Average $11.83 (+291.8% upside)

Low: $10.10
Now: $3.02
High: $13.65

Upgrades and downgrades

The latest rating actions, newest first

XFOR analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
Wells Fargo	Jul 10, 2026	Initiates	Overweight	$11.00	54%
Leerink Partners	Jun 2, 2026	Initiates	Outperform	$12.00	25%
Guggenheim	Mar 9, 2026	Initiates	Buy	$12.00	62%
Stifel	Dec 5, 2025	Maintains	Buy	$7.50 → $10.00	36%
HC Wainwright & Co.	Nov 10, 2025	Maintains	Buy	$3.50 → $5.00	43%

The case for and against

Updated Apr 28, 2026

Bull case

X4 Pharmaceuticals is a Buy with a $10 target price, as the company is well-positioned for success in their pivotal, ph3 trial for mavorixafor as a treatment for chronic neutropenia. With a new strong management team and a shored-up balance sheet, all necessary pieces are in place for investors to confidently expect a high-POS, blockbuster opportunity for mavorixafor in the near future. Additionally, prior data for the drug has shown promising results in both Phase 1b and Phase 2 studies, further supporting our positive outlook.

Bear case

X4 Pharmaceuticals is currently facing some fundamental challenges, particularly in their ongoing clinical trial for mavorixafor as a therapy for chronic neutropenia. Despite strong design and conservative powering of the trial, there are still concerns about a potential lack of efficacy in reducing infections, which remains a major question mark for the drug's success. Additionally, recent corporate restructuring and strategic changes may indicate a lack of confidence in their existing pipeline, with resources being refocused on their Phase 3 study. There is also a high level of dilution risk for investors, with a recent secondary offering and private placement leaving the company well-funded but also potentially diluting shareholder value.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.